{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:57:27Z","timestamp":1793055447438,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vhri.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:36:50Z","timestamp":1680284210000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece"],"prefix":"10.1016","volume":"36","author":[{"given":"Charalampos","family":"Tzanetakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.vhri.2023.02.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the Estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2023.02.006_bib2","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10198-020-01193-w","article-title":"Awaiting the \u201ccatharsis\u201d","volume":"22","author":"Yfantopoulos","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.vhri.2023.02.006_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: the past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob Health Action"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jval.2017.12.008","article-title":"Objectives, budgets, thresholds, and opportunity costs-A health economics approach: an ISPOR Special Task Force Report [4]","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40273-015-0336-1","article-title":"The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to unintended harm to Ireland\u2019s health system?","volume":"34","author":"O\u2019Mahony","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vhri.2023.02.006_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","article-title":"Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines","volume":"32","author":"Newall","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.vhri.2023.02.006_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186496","article-title":"Revealed willingness-to-pay versus standard cost-effectiveness thresholds: evidence from the South African HIV Investment Case","volume":"12","author":"Meyer-Rath","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/heapol\/czw096","article-title":"Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds","volume":"32","author":"Robinson","year":"2017","journal-title":"Health Policy Plan"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2023.02.006_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","article-title":"The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review","volume":"25","author":"Kazibwe","year":"2022","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib14","first-page":"444","article-title":"Implementing health technology assessment (HTA) in Greece: myths, reality andcautionary tales","volume":"36","author":"Kanavos","year":"2019","journal-title":"Arch Hellenic Med"},{"issue":"12","key":"10.1016\/j.vhri.2023.02.006_bib15","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1016\/j.jval.2022.09.1207","article-title":"HPR76 implementing the recovery and resilience fund initiative to reduce pharmaceutical expenditure clawback in Greece: the impact on pharmaceutical spending and on national economy","volume":"25","author":"Mylonas","year":"2022","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib18","first-page":"289","article-title":"Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece","volume":"54","author":"Andrikopoulos","year":"2013","journal-title":"Hellenic J Cardiol"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib19","doi-asserted-by":"crossref","first-page":"A608","DOI":"10.1016\/j.jval.2015.09.2102","article-title":"Cost-effectiveness of sitagliptin compared to sulphonylurea as an add-on to metformin in the treatment of Type 2 diabetes in Greece","volume":"18","author":"Athanasakis","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CEOR.S107831","article-title":"Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece","volume":"8","author":"Athanasakis","year":"2016","journal-title":"Clinicoeconomics Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40256-016-0204-1","article-title":"Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective","volume":"17","author":"Athanasakis","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.vhri.2023.02.006_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.clinthera.2017.03.019","article-title":"Cost-effectiveness of ingenol mebutate gel for the treatment of actinic keratosis in Greece","volume":"39","author":"Athanasakis","year":"2017","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.clinthera.2015.05.003","article-title":"Boceprevir for chronic Genotype 1 hepatitis C virus in the current health care setting in Greece: a cost-effectiveness analysis","volume":"37","author":"Athanasakis","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clinthera.2012.01.005","article-title":"Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece","volume":"34","author":"Athanasakis","year":"2012","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.vhri.2023.02.006_bib25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2012.07.002","article-title":"Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece","volume":"34","author":"Athanasakis","year":"2012","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.vhri.2023.02.006_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40261-015-0321-7","article-title":"Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting","volume":"35","author":"Athanasakis","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2377-13-56","article-title":"Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting","volume":"13","author":"Athanasakis","year":"2013","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.vhri.2023.02.006_bib28","first-page":"678","article-title":"Posaconazole vs fluconazole\/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece","volume":"16","author":"Athanasakis","year":"2013","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib29","doi-asserted-by":"crossref","first-page":"A671","DOI":"10.1016\/j.jval.2015.09.1971","article-title":"Cost-effectiveness analysis of tocilizumab subcutaneous as first line biologic monotherapy for rheumatoid arthritis management in Greece","volume":"18","author":"Athanasakis","year":"2015","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00296-015-3253-x","article-title":"Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece","volume":"35","author":"Athanasakis","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vhri.2023.02.006_bib31","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jval.2018.09.268","article-title":"PCN185 - cost-effectiveness of nivolumab in second-line treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prion platinum-containing therapy in Greece","volume":"21","author":"Boukouvalas","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib32","doi-asserted-by":"crossref","first-page":"A454","DOI":"10.1016\/j.jval.2011.08.1211","article-title":"Economic evaluation of gefitinib for first-line treatment of EGFR mutation positive advanced non-small cell lung cancer patients in Greece","volume":"14","author":"Fragoulakis","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S43373","article-title":"Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece","volume":"5","author":"Fragoulakis","year":"2013","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib34","doi-asserted-by":"crossref","first-page":"A104","DOI":"10.1016\/j.jval.2012.03.569","article-title":"PSY35 economic evaluation of lenalidomide in the management of previously treated multiple myeloma patients in Greece","volume":"15","author":"Fragoulakis","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CEOR.S31972","article-title":"Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece","volume":"4","author":"Fragoulakis","year":"2012","journal-title":"Clinicoeconomics Outcomes Res"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib36","doi-asserted-by":"crossref","first-page":"A632","DOI":"10.1016\/j.jval.2014.08.2263","article-title":"Economic evaluation of NAB-paclitaxel plus gemcitabine versus gemcitabine alone for the management of metastatic pancreatic cancer in Greece","volume":"17","author":"Fragoulakis","year":"2014","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib37","doi-asserted-by":"crossref","first-page":"A500","DOI":"10.1016\/j.jval.2015.09.1414","article-title":"Cost-effectiveness analysis of the fixed combination indacaterol\/glycopyrronium vs. tiotropium and salmeterol\/ fluticasone in the management of Copd in Greece","volume":"18","author":"Geitona","year":"2015","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib38","first-page":"359","article-title":"Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system","volume":"22","author":"Geitona","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.vhri.2023.02.006_bib39","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jval.2018.09.2026","article-title":"PND60 - Cost-effectiveness of teriflunomide for the treatment of relapsing-remitting multiple sclerosis in Greece","volume":"21","author":"Gourzoulidis","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib40","doi-asserted-by":"crossref","first-page":"A436","DOI":"10.1016\/j.jval.2017.08.219","article-title":"Cost-effectiveness of ponatinib in the treatment of patients with accelerated or Blast Phase - chronic myeloid leukemia in Greece","volume":"20","author":"Gourzoulidis","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib41","doi-asserted-by":"crossref","first-page":"A435","DOI":"10.1016\/j.jval.2017.08.212","article-title":"Cost-effectiveness of ponatinib in the treatment of patients with chronic phase- chronic myeloid leukemia in Greece","volume":"20","author":"Gourzoulidis","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40261-017-0540-1","article-title":"Cost-effectiveness analysis of Rivaroxaban for treatment of deep vein thrombosis and pulmonary embolism in Greece","volume":"37","author":"Gourzoulidis","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.vhri.2023.02.006_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/cer-2018-0076","article-title":"Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece","volume":"8","author":"Gourzoulidis","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"issue":"5","key":"10.1016\/j.vhri.2023.02.006_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40261-018-0620-x","article-title":"Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece","volume":"38","author":"Gourzoulidis","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.vhri.2023.02.006_bib45","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jval.2018.09.1755","article-title":"PMS41 - Cost-effectiveness analyis of tofacitinib in combination with methotrexate of moderate to severe rheumatoid arthritis in Greece","volume":"21","author":"Kourkoulas","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib46","first-page":"A633","article-title":"Cost-effectiveness analysis of panitumumab+Mfolfox over bevacizumab+Mfolfox as a first-line treatment for metastatic colorectal cancer patients with wild-type Ras in Greece","volume":"17","author":"Kourlaba","year":"2014","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2023.02.006_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF03261867","article-title":"Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece","volume":"10","author":"Kourlaba","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11633820-000000000-00000","article-title":"Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis","volume":"10","author":"Kourlaba","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12913-016-1779-6","article-title":"Economic evaluation of trimetazidine in the management of chronic stable angina in Greece","volume":"16","author":"Kourlaba","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-7547-12-5","article-title":"Economic evaluation of Rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece","volume":"12","author":"Kourlaba","year":"2014","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib51","doi-asserted-by":"crossref","first-page":"A372","DOI":"10.1016\/j.jval.2012.08.997","article-title":"PCV54 economic evaluation of Rivaroxaban in the treatment of deep vein thrombosis in Greece","volume":"15","author":"Kourlaba","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib52","doi-asserted-by":"crossref","first-page":"A87","DOI":"10.1016\/j.jval.2012.03.478","article-title":"PMH33 economic evaluation of agomelatine for major depressive disorders in the Greek setting","volume":"15","author":"Kourlaba","year":"2012","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib53","first-page":"A633","article-title":"Cost-effectiveness and cost-utility of granulocyte colony-stimulating factors in the primary prophylaxis of chemotherapy induced febrile neutropenia (FN) in breast cancer patients in Greece: a comparative analysis","volume":"17","author":"Kourlaba","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib54","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/s12913-014-0631-0","article-title":"Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece","volume":"14","author":"Kourlaba","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12913-015-0971-4","article-title":"Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: an economic evaluation study","volume":"15","author":"Kourlaba","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vhri.2023.02.006_bib56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12962-016-0056-1","article-title":"Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema","volume":"14","author":"Kourlaba","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib57","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12913-015-1228-y","article-title":"Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study","volume":"15","author":"Kourlaba","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib58","doi-asserted-by":"crossref","first-page":"A555","DOI":"10.1016\/j.jval.2017.08.888","article-title":"A\u00a0cost effectiveness analysis of obinutuzumab in the management of chronic lymphocytic leukemia in Greece","volume":"20","author":"Kousoulakou","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib59","doi-asserted-by":"crossref","first-page":"A399","DOI":"10.1016\/S1098-3015(11)72641-9","article-title":"PSS12 Economic evaluation of ranibizumab in the treatment of age-related macular degeneration in Greece","volume":"13","author":"Maniadakis","year":"2010","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib60","doi-asserted-by":"crossref","first-page":"A310","DOI":"10.1016\/j.jval.2011.08.431","article-title":"PMS45 cost-utility and budget impact analysis of certolizumab pegol plus methotrexate for the treatment of moderate-to-severe active rheumatoid arthritis in Greece","volume":"14","author":"Maniadakis","year":"2011","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1472-6963-13-173","article-title":"Economic evaluation of agomelatine relative to other antidepressants for treatment\u00a0of\u00a0major depressive disorders in Greece","volume":"13","author":"Maniadakis","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib62","doi-asserted-by":"crossref","first-page":"A732","DOI":"10.1016\/j.jval.2016.09.2208","article-title":"Economic evaluation of olaparib in patients with brca mutated Psroc in Greece","volume":"19","author":"Mylonas","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib63","doi-asserted-by":"crossref","first-page":"A486","DOI":"10.1016\/j.jval.2014.08.1424","article-title":"Economic evaluation of ferric carboxymaltose in patients with chronic heart failure and iron deficiency: an analysis for Greece based on fair-Hf trial","volume":"17","author":"Mylonas","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib64","first-page":"A417","article-title":"Economic evaluation of AbbVie\u2019s regimen (Viekirax\/Exviera) for patients with genotype 1b Hcv in Greece","volume":"19","author":"Mylonas","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib65","doi-asserted-by":"crossref","first-page":"A418","DOI":"10.1016\/j.jval.2016.09.412","article-title":"Economic evaluation of AbbVie\u2019s regimen (Viekirax) for patients with Genotype 4 Hcv in Greece","volume":"19","author":"Mylonas","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib66","doi-asserted-by":"crossref","first-page":"A458","DOI":"10.1016\/j.jval.2014.08.1260","article-title":"Economic evaluation of nalmefene for the treatment of alcohol dependence in Greece","volume":"17","author":"Relakis","year":"2014","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib67","doi-asserted-by":"crossref","first-page":"A732","DOI":"10.1016\/j.jval.2016.09.2206","article-title":"Economic evaluation of everolimus as second-line treatment of metastatic renal cell carcinoma in Greece","volume":"19","author":"Solakidi","year":"2016","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib68","doi-asserted-by":"crossref","first-page":"A645","DOI":"10.1016\/j.jval.2017.08.1491","article-title":"Cost-effectiveness of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Greece","volume":"20","author":"Solakidi","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib69","doi-asserted-by":"crossref","first-page":"A534","DOI":"10.1016\/j.jval.2017.08.766","article-title":"Cost-effectiveness analysis of apremilast for the treatment of active psoriatic arthritis in Greece","volume":"20","author":"Solakidi","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib70","doi-asserted-by":"crossref","first-page":"A803","DOI":"10.1016\/j.jval.2017.08.2394","article-title":"Cost-effectiveness of apremilast for the treatment of moderate to severe psoriasis in Greece","volume":"20","author":"Solakidi","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib71","doi-asserted-by":"crossref","first-page":"A597","DOI":"10.1016\/j.jval.2014.08.2065","article-title":"Economic evaluation of omalizumab compared with standard therapy in the treatment of severe allergic asthma in adult patients in Greece: a cost effectiveness analysis based on clinical trial and real-world data","volume":"17","author":"Sonathi","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib72","doi-asserted-by":"crossref","first-page":"A370","DOI":"10.1016\/j.jval.2012.08.987","article-title":"Economic evaluation of a single-pill triple combination with valsartan, amlodipine and hydrochlorothiazide against its dual components in Greece. The generic substitution case","volume":"15","author":"Stafylas","year":"2012","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib73","doi-asserted-by":"crossref","first-page":"A654","DOI":"10.1016\/j.jval.2016.09.1770","article-title":"Cost-utility analysis of Sacubitril\/Valsartan for the treatment of chronic heart failure in Greece","volume":"19","author":"Stafylas","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib74","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jval.2018.09.622","article-title":"PCV76 - Cost-Effectiveness analysis of Rivaroxaban in the secondary prevention of acute coronary syndromes in Greece","volume":"21","author":"Stafylas","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib75","doi-asserted-by":"crossref","first-page":"A371","DOI":"10.1016\/j.jval.2012.08.996","article-title":"Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components","volume":"15","author":"Stafylas","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12962-015-0036-x","article-title":"Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components","volume":"13","author":"Stafylas","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib77","doi-asserted-by":"crossref","first-page":"A489","DOI":"10.1016\/j.jval.2014.08.1443","article-title":"Economic evaluation of valsartan versus olmesartan addition to amlodipine and hydrochlorothiaziade single-pill triple antihypertensive therapy","volume":"17","author":"Stafylas","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.vhri.2023.02.006_bib78","first-page":"766","article-title":"A\u00a0cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy","volume":"22","author":"Terpos","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40261-017-0586-0","article-title":"Cost effectiveness of exenatide once weekly versus insulin glargine and liraglutide for the treatment of type 2 diabetes mellitus in Greece","volume":"38","author":"Tzanetakos","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib80","doi-asserted-by":"crossref","first-page":"A569","DOI":"10.1016\/j.jval.2016.09.1286","article-title":"Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece","volume":"19","author":"Tzanetakos","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib81","doi-asserted-by":"crossref","first-page":"A646","DOI":"10.1016\/j.jval.2015.09.2319","article-title":"Cost-utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece","volume":"18","author":"Tzanetakos","year":"2015","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1472-6963-14-419","article-title":"Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece","volume":"14","author":"Tzanetakos","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"10.1016\/j.vhri.2023.02.006_bib83","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40261-016-0410-2","article-title":"Cost-effectiveness of dapagliflozin as add-On to metformin for the treatment of type 2 diabetes mellitus in Greece","volume":"36","author":"Tzanetakos","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib84","doi-asserted-by":"crossref","first-page":"A438","DOI":"10.1016\/j.jval.2017.08.232","article-title":"Cost-effectiveness of ponatinib in the treatment of patients with acute lymphoblastic leukemia with Philadelphia chromosome positive (PH+ ALL), suitable for allogeneic stem cell transplant, in Greece","volume":"20","author":"Vellopoulou","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib85","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1016\/j.jval.2018.09.2435","article-title":"PRS41 - Cost-Effectiveness of pirfenidone for the treatment of patients with mild to moderate idiopathic pulmonary fibrosis in Greece","volume":"21","author":"Vellopoulou","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib86","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jval.2018.09.224","article-title":"PCN141 - Cost-Effectiveness analysis of Obinutuzumab for the treament of patients with previously untreated advanced follicular lymphoma in Greece","volume":"21","author":"Vellopoulou","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib87","doi-asserted-by":"crossref","first-page":"A765","DOI":"10.1016\/j.jval.2017.08.2178","article-title":"Cost-effectiveness analysis of insulin degludec U100 compared with insulin glargine U100 in Greece","volume":"20","author":"Yfantopoulos","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib88","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/j.jval.2019.09.365","article-title":"PCN169 Cost-Effectiveness analysis of Nivolumab in combination with ipilimumab for the first-line treatment of advanced\/metastatic renal cell carcinoma in Greece","volume":"22","author":"Diamantogiannis","year":"2019","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.vhri.2023.02.006_bib89","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40261-019-00827-z","article-title":"Cost-effectiveness analysis of Erenumab versus onabotulinumtoxinA for patients with chronic migraine attacks in Greece","volume":"39","author":"Giannouchos","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib90","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jval.2021.11.481","article-title":"POSC76 cost-utility analysis of pegaspargase for the treatment of acute lymphoblastic leukemia in Greece","volume":"25","author":"Gourzoulidis","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14737167.2021.1921576","article-title":"Cost-effectiveness of trifluridine\/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece","volume":"22","author":"Gourzoulidis","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2023.02.006_bib92","first-page":"S422","article-title":"PBI28 Cost-Effectiveness of certolizumab pegol for the treatment of moderate to severe plaque psoriasis in Greece","volume":"22","author":"Gourzoulidis","year":"2019","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2023.02.006_bib93","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40261-021-01013-w","article-title":"Cost-effectiveness of empagliflozin compared with dapagliflozin for the treatment of patients with type 2 diabetes mellitus and established cardiovascular disease in Greece","volume":"41","author":"Gourzoulidis","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.vhri.2023.02.006_bib94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.36469\/jheor.2022.32983","article-title":"Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece","volume":"9","author":"Gourzoulidis","year":"2022","journal-title":"J\u00a0Health Econ Outcomes Res"},{"key":"10.1016\/j.vhri.2023.02.006_bib95","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/j.jval.2019.09.414","article-title":"PCN218 Cost-effectiveness of Apalutamide+ADT versus Enzalutamide+ADT in non-metastatic castration resistant prostate cancer in Greece","volume":"22","author":"Tsiatas","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2023.02.006_bib96","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MEG.0000000000001916","article-title":"Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece","volume":"33","author":"Vellopoulou","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.vhri.2023.02.006_bib97","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1016\/j.jval.2020.08.207","article-title":"PCN70 cost effectiveness analysis of pembrolizumab in the treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection - the Greek setting","volume":"23","author":"Yfantopoulos","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib98","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00296-017-3736-z","article-title":"Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece","volume":"37","author":"Tzanetakos","year":"2017","journal-title":"Rheumatol Int"},{"issue":"17","key":"10.1016\/j.vhri.2023.02.006_bib99","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1517\/14656566.2011.628935","article-title":"A\u00a0cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease","volume":"12","author":"Lock","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.vhri.2023.02.006_bib100","doi-asserted-by":"crossref","first-page":"A724","DOI":"10.1016\/j.jval.2017.08.1953","article-title":"Lacosamide as first line treatment option in focal epilepsy; a cost-utility analysis for the Greek healthcare system","volume":"20","author":"Geitona","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib101","doi-asserted-by":"crossref","first-page":"A675","DOI":"10.1016\/j.jval.2014.08.2506","article-title":"Cost-effectiveness analysis of raltegravir in Hiv-infected treatment naive patients in Greece","volume":"17","author":"Athanasakis","year":"2014","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib102","doi-asserted-by":"crossref","first-page":"A532","DOI":"10.1016\/j.jval.2014.08.1694","article-title":"Belimumab for the treatment of systemic lupus erythematosus (Sle) in Greece: a cost-effectiveness and cost-utility analysis","volume":"17","author":"Athanasakis","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.vhri.2023.02.006_bib103","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.clinthera.2013.06.004","article-title":"A\u00a0cost-effectiveness analysis of parecoxib in the management of postoperative pain in the Greek health care setting","volume":"35","author":"Athanasakis","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.vhri.2023.02.006_bib104","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jval.2018.09.257","article-title":"PCN174 - NEPA, an oral fixed combination of netupitant and palonosetron, is cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in Germany and Greece","volume":"21","author":"Bourhis","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib105","doi-asserted-by":"crossref","first-page":"A270","DOI":"10.1016\/S1098-3015(10)74324-2","article-title":"PCN73 Cost-effectiveness od adding zoledronic acid to endocrine therapy in premenopausal women with hormone -responsive Eary breast cancer in Greece, based on the ABCSG-12 study","volume":"12","author":"Delea","year":"2009","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib106","doi-asserted-by":"crossref","first-page":"A421","DOI":"10.1016\/j.jval.2012.08.2109","article-title":"PCN69 cost-effectiveness analysis of maintenance treatment with rituximab (MabThera) for non-Hodgkins lymphoma patients in Greece, a local adaptation","volume":"15","author":"Demousis","year":"2012","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib107","doi-asserted-by":"crossref","first-page":"A424","DOI":"10.1016\/j.jval.2012.08.2124","article-title":"PCN84 abiraterone acetate versus cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: an economic evaluation in the Greek health care setting","volume":"15","author":"Efstathiou","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib108","first-page":"135","article-title":"Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece","volume":"4","author":"Fragoulakis","year":"2012","journal-title":"Clinicoeconomics Outcomes Res"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib109","doi-asserted-by":"crossref","first-page":"A479","DOI":"10.1016\/j.jval.2011.08.1345","article-title":"PDB42 economic evaluation of recombinant human FSH in comparison with urinary HMG in assisted reproduction in the Greek setting","volume":"14","author":"Fragoulakis","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib110","doi-asserted-by":"crossref","first-page":"A512","DOI":"10.1016\/j.jval.2012.08.1747","article-title":"PSY24 economic evaluation of opioid substitution treatment (OST) in Greece","volume":"15","author":"Geitona","year":"2012","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib111","doi-asserted-by":"crossref","first-page":"A493","DOI":"10.1016\/j.jval.2011.08.1422","article-title":"PRS35 economic evaluation of indacaterol versus tiotropium or formoterol for patients with moderate to severe Copd in Greece","volume":"14","author":"Geitona","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib112","doi-asserted-by":"crossref","first-page":"A397","DOI":"10.1016\/j.jval.2014.08.896","article-title":"Economic evaluation of lacosamide in the management of epileptic partial onset seizures in Greece","volume":"17","author":"Geitona","year":"2014","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib113","doi-asserted-by":"crossref","first-page":"A457","DOI":"10.1016\/j.jval.2015.09.1173","article-title":"Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma in Greece","volume":"18","author":"Gourzoulidis","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib114","first-page":"S442","article-title":"PCN108 the cost-effectiveness of liposomal irinotecan and 5-fluorouracil (5-FU)\/ leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of pancreas who have progressed following the use of gemcitabine-related therapies in Greece","volume":"23","author":"Gourzoulidis","year":"2020","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib115","doi-asserted-by":"crossref","first-page":"A501","DOI":"10.1016\/j.jval.2012.08.1686","article-title":"PDB43 economic evaluation of vildagliptin compared to glimepiride as add-on to metformin for the treatment of diabetes mellitus type 2 patients in Greece","volume":"15","author":"Hatzikou","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib116","doi-asserted-by":"crossref","first-page":"A432","DOI":"10.1016\/j.jval.2017.08.197","article-title":"Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from checkmate 067","volume":"20","author":"Hirst","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib117","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.jval.2019.09.282","article-title":"PCN85 Cost-Effectiveness of Tisagenlecleucel in paediatric and young adult relapsed or refractory B-cell acute lymphobastic leukaemia, from a Greek social secutiry system perspective","volume":"22","author":"Kattamis","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib118","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jval.2018.09.2025","article-title":"PND59 - Cost-effectiveness analysis of alemtuzumab as a treatment option for patients with multiple sclerosis in Greece","volume":"21","author":"Kourkoulas","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib119","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jval.2018.09.231","article-title":"Cost-effectiveness analysis of atezolizumab compared to treatment options for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy- updated results","volume":"21","author":"Kourkoulas","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib120","doi-asserted-by":"crossref","first-page":"A439","DOI":"10.1016\/j.jval.2017.08.233","article-title":"Cost-effectiveness analysis of atezolizumab compared to the standard of care for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in Greece","volume":"20","author":"Kourkoulas","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2023.02.006_bib121","doi-asserted-by":"crossref","first-page":"A433","DOI":"10.1016\/j.jval.2017.08.200","article-title":"Cost-effectiveness analysis of alectinib compared to chemotherapy for the treatment of patients with Alk positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in Greece","volume":"20","author":"Kourkoulas","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib122","doi-asserted-by":"crossref","first-page":"A456","DOI":"10.1016\/j.jval.2015.09.1166","article-title":"Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Greece","volume":"18","author":"Kourlaba","year":"2015","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib123","doi-asserted-by":"crossref","first-page":"A421","DOI":"10.1016\/j.jval.2015.09.557","article-title":"Cost-effectiveness analysis of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration in Greece","volume":"18","author":"Kourlaba","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12962-017-0082-7","article-title":"Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece","volume":"15","author":"Kousoulakou","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib125","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/j.jval.2011.08.803","article-title":"PCV83 a cost-effectiveness analysis of ticagrelor in patients with acute coronary syndrome in Greece","volume":"14","author":"Kritikou","year":"2011","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2023.02.006_bib126","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10198-010-0243-5","article-title":"Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece","volume":"12","author":"Maniadakis","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib127","doi-asserted-by":"crossref","first-page":"A357","DOI":"10.1016\/S1098-3015(11)72429-9","article-title":"PCV86 Economic evaluation of dronedarone in treatment of atrial fibrillation in Greece","volume":"13","author":"Maniadakis","year":"2010","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib128","doi-asserted-by":"crossref","first-page":"A735","DOI":"10.1016\/j.jval.2016.09.2222","article-title":"Economic evaluation of pertuzumab neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage HER2-positive breast cancer in Greece","volume":"19","author":"Mylonas","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib129","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.jval.2019.09.778","article-title":"PCV53 Cost-effectiveness of the CNIC polypoll-fixed dose combination of acetylsalicylic acid, ramipril and atorvastatin for the secondary prevention of cardiovascular disease in Greece","volume":"22","author":"Ntaios","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib130","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1016\/j.jval.2018.09.2532","article-title":"PSS32 - Cost-Effectiveness of Brodalumab for the treatment of moderate to severe plaque psoriasis in Greece","volume":"21","author":"Solakidi","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2023.02.006_bib131","doi-asserted-by":"crossref","first-page":"A516","DOI":"10.1016\/j.jval.2012.08.1767","article-title":"PSY44 A cost effectiveness model for the Myeloplastic disease in Greece. Azacitidine versus conventional care regimens","volume":"15","author":"Yfantopoulos","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.02.006_bib132","doi-asserted-by":"crossref","first-page":"A394","DOI":"10.1016\/j.jval.2012.08.1117","article-title":"PIN50 a cost-effectiveness analysis of telaprevir versus Boceprevir in the treatment of hepatitis C: a Greek national health system perspective","volume":"15","author":"Yfantopoulos","year":"2012","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.vhri.2023.02.006_bib133","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.vhri.2023.02.006_bib134","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/heapol\/czx166","article-title":"Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia","volume":"33","author":"Loganathan","year":"2018","journal-title":"Health Policy Plan"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib136","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vhri.2023.02.006_bib137","author":"Karlsberg Schaffer"},{"key":"10.1016\/j.vhri.2023.02.006_bib138","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/CEOR.S87462","article-title":"Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold","volume":"7","author":"Griffiths","year":"2015","journal-title":"Clinicoeconomics Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib139","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.02.006_bib140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jval.2017.12.010","article-title":"Approaches to aggregation and decision making-a health economics approach: an ISPOR Special Task Force Report [5]","volume":"21","author":"Phelps","year":"2018","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:48Z","timestamp":1761941688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923000250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":140,"alternative-id":["S2212109923000250"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.02.006","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}